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ABSTRACT
Nitric oxide (NO) is a small gas molecule derived from at least three isoforms of the enzyme termed nitric oxide synthase (NOS). More 
than 15 years ago, the question of feedback regulation of NOS activity and expression by its own product was raised. Since then, a 
number of trials have verified the existence of negative feedback loop both in vitro and in vivo. NO, whether released from exogenous 
donors or applied in authentic NO solution, is able to inhibit NOS activity and also intervenes in NOS expression processes by its 
effect on transcriptional nuclear factor NF-κB. The existence of negative feedback regulation of NOS may provide a powerful tool for 
experimental and clinical use, especially in inflammation, when massive NOS expression may be detrimental. 
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Nitric oxide synthase
The enzyme, which NO is derived from, bears the name 
‘nitric oxide synthase’ (NOS, EC 1.14.13.39). To date, 
NOS has been purified in at least three isoforms, which 
can be distinguished by their origin from different genes, 
diverse localization within the cell, specific regulation 
and various sensitivity to inhibitors, with about 51–57% 
homology between the human isoforms (Geller & Billiar, 
1998; Alderton et al., 2001).
The typical nomenclature of NOS isoforms is derived 
from the tissue of the first isolation, although occurrence 
of particular isoforms is not strictly limited to a certain 
type of cells. Thus the isoform first purified from rat brain 
tissue is called neuronal NOS (nNOS) or NOS I (Bredt et 
al., 1990). In addition to neurons, nNOS may be exprimed 
also in skeletal muscles, lung epithelial cells, kidneys, 
adrenal glands, skin, hypophysis, vascular smooth muscle 
cells and other cells and tissues (Boulanger et al., 1998; 
Förstermann et al., 1998; Esper et al., 2006). 
NO synthesized by nNOS participates primarily in 
neurotransmission and neuromodulation. In the nucleus 
tractus solitarii and rostral ventrolateral medulla, the 
function of nNOS is related to central control of blood 
pressure (Chang et al., 2003; Lin et al., 2007). In the 
periphery, NO acts as neurotransmitter in perivascular 
vasodilatory nerves named ‘nitrergic’ and sometimes 
is considered to be the main neurotransmitter of the 
inhibitory non-adrenergic non-cholinergic system 
(Antošová et al., 2005). However, in the case of eNOS 
knock-out mice, nNOS was also able to supply the role of 
Physiological function of nitric oxide 
synthase feedback regulation
Nitric oxide (NO) is a small gas molecule participating 
in physiological processes in diverse cells from protozoan 
parasite Leishmania donovani to mammalian neurocytes 
(Basu et al., 1997). Nevertheless, many biochemical char-
acteristics of its synthesis remain as yet unknown.
It seems almost unbelievable what a long time has 
passed since Hermann found in 1865 that NO combines 
with hemoglobin. Later NO was shown to react with the 
heme groups and nearly hundred years later the kinetics 
and equilibrium of the reaction of NO with hemoglobin 
was described (Gibson & Roughton, 1957). The ability 
of NO to activate heme protein guanylate cyclase and 
to increase the level of cyclic guanosine monophosphate 
(cGMP) in various tissues (Arnold et al., 1977) raised 
the question about the physiological role of NO and the 
ensuing quest for an answer gave birth to the discovery 
of NO-mediated cGMP-dependent vasorelaxation 
(Rapoport & Murad, 1983).
During the following ten years, the nature of divergent 
physiological functions of NO was discovered along with 
distinct isoforms of NO-synthesizing enzyme.
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eNOS in vasorelaxation (Meng et al., 1998). Additionally, 
nNOS-derived NO functions also in synaptic plasticity, 
including hippocampal long-term potentiation, and plays 
an important role in stress and adaptive responses of 
the organism (Bon & Garthwaite, 2003; Púzserová et al., 
2006; Bernátová et al., 2007a). 
Endothelial NOS (eNOS) or NOS III was purified 
from bovine aortic endothelial cells (Pollock et al., 1991) 
and may be found also in cardiomyocytes, hepatocytes, 
thrombocytes, vascular smooth muscle cells, lung epi-
thelial cells and others (Förstermann et al., 1998; Arnal 
et al., 1999; Strapková et al., 2008). In the cell, eNOS is 
typically targeted into plasmalemmal invaginations 
termed ‘caveolae’, which inhibits eNOS function. Increase 
in intracellular Ca2+ concentration, e.g. by shear stress, 
leads to the formation of calcium/calmodulin complex 
(Ca2+/CaM), which enables eNOS to dissociate from 
caveolae and become catalytically active (Alderton et al., 
2001). Endothelial NO has a variety of physiological func-
tions, including vasodilatation, inhibition of thrombocyte 
adhesion and aggregation and antiatherogenic effects 
(Esper et al., 2006).
Both isoforms mentioned above are considered to be 
expressed constitutively. At least in some tissues their 
activity is Ca2+-dependent and their NO production 
reaches picomolar levels (Strapková & Nosáľová, 2001).
Inducible NOS (iNOS) or NOS II is the last of three 
isoforms of NO-synthesizing enzyme, purified for the 
first time from activated macrophages (Hevel et al., 
1 9 9 1 ) .  B y  c o n t r a s t  t o  s o - c a l l e d  c o n s t i t u t i v e  i s o f o r m s  
(nNOS and eNOS), iNOS had been earlier thought to be 
Ca2+-independent and expressed after induction under 
inflammatory conditions (Geller & Billiar, 1998).
While induction of iNOS expression in murine and 
rat cells requires incubation with just one bacterial 
lipopolysacharide (LPS), IL-1β, IL-6, TNF-α or an other 
compound, in the majority of human cells it requires 
a complex cytokine combination (Kleinert et al., 2004). 
After stimulation, a variety of cells are able to express 
iNOS, e.g. hepatocytes, monocytes, mast cells, cardiac 
myocytes, glial cells or vascular smooth muscle cells 
(Michel & Feron, 1997; Aktan, 2004). In contradistinction 
to the generally held opinion, some specific cells such 
as murine ileal epithelium, epithelium of bronchi and 
bronchioles of lamb and sheep or human airway epithe-
lium showed also constitutive expression of iNOS (Guo 
et al., 1995; Hoffman et al., 1997; Sherman et al., 1999). 
This may be further enhanced in the presence of certain 
factors such as LPS (Gath et al., 1996) or oxidative stress 
(Cooke & Davidge, 2002) and, on the contrary, suppressed 
by glucocorticoid treatment (Guo et al., 1995).
Once induced, iNOS produces continuously high 
levels of NO up to micromolar range, until the enzyme is 
degraded (Geller & Billiar, 1998). The high output of NO 
from iNOS acts in antimicrobial, antiviral, antiparasitic 
and tumoricidal processes (MacMicking et al., 1997; 
Geller & Billiar, 1998) and the cytotoxic effect of NO is 
involved in immunological and tissue-damaging actions 
(Bogdan, 2001). On the other hand, excessive production 
of NO participates in the pathophysiology of several 
autoimmune diseases (for example Crohn’s disease, rheu-
matoid arthritis), chronic inflammatory diseases (such 
as asthma), acute lung injury and meconium aspiration 
syndrome or various degenerative diseases (Kröncke et 
al., 1998; Bogdan, 2001).
Enzymatic action of NOS
Only a homodimeric enzyme is able to produce NO 
coupling L-arginine oxidation to NADPH consumption 
and releasing L-citrulline as coproduct. Several cofactors 
are necessary for stable dimerization of NOS and NO 
synthesis. For each monomer, heme and flavins (flavin 
adenine dinucleotide and flavin mononucleotide) as pros-
thetic groups are required to tightly bind to the molecule. 
Ca2+/CaM and 5,6,7,8-tetrahydrobiopterin (BH4) binding 
to monomer provide both dimerization and solely enzy-
matic action, while zinc ion is required one per dimer for 
stabilization (Geller & Billiar, 1998; Alderton et al., 2001).
Ca2+/CaM binding to NOS dimer reflects intracellular 
Ca2+ concentration and if it decreases, the bond dissoci-
ates and electron transport stops (Daff et al., 1999). This 
is the basis for the activity of constitutively expressed 
NO synthases to be calcium-regulated. Synthesis of NO 
during catalytic activity of iNOS had been formerly con-
sidered to be Ca2+-independent, but contrary to previous 
views, the activity of iNOS isolated from guinea-pig lungs 
could be inhibited by chelation of Ca2+ ions (Shirato et al., 
1998). Likewise, human iNOS seems to require at least 
a low level of calcium for optimal binding of calmodulin 
(Geller & Billiar, 1998).
Yet another factor, BH4, is crucial for physiological 
action of NOS, especially for iNOS (Alderton et al., 2001). 
In the absence of BH4 (or L-arginine), the phenomenon 
called “uncoupling” occurs, which means that NADPH 
consumption proceeds independently of L-arginine 
oxidation. NOS will utilize NADPH, but in that case 
the product of reaction is superoxide anion (O2
–) and 
H2O2 (Gorren & Mayer, 2002). At limiting concentra-
tions, the situation becomes more complicated. If there 
is just one BH4 per NOS dimer, the BH4-free subunit 
will produce O2
– in the uncoupled reaction, while the 
BH4-supplemented subunit will produce NO (Gorren et 
al., 1996). Taking into consideration that NO and super-
oxide can react together rapidly forming peroxynitrite, 
NO synthase may act as peroxynitrite synthase (Andrew 
& Mayer, 1999). As a consequence, the bioavailability of 
BH4 for NOS further declines, as peroxynitrite oxidizes 
BH4 to inactive dihydro-L-biopterin (Milstien & Katusic, 
1999) and more NOS reactions become uncoupled.
Excessive formation of O2
– or peroxynitrite after 
cytokine-mediated NOS expression, for example in acute 
lung injury (such as in meconium aspiration syndrome), 
may exceed the capacity of the oxidant defense system 
leading to oxidative stress. This may potentiate the lung 
injury and inhibit lung surfactant production (Mokra & 
Mokry, 2007; 2010)65
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Feedback regulation of NOS activity
Potential NO-mediated oxidative damage requires 
d e t a i l e d  r e g u l a t i o n  o f  N O S  a c t i v i t y  a s  w e l l  a s  N O S  
expression.
Besides carefully managed conditions of dimer acti-
vation by cofactors, the question of feedback regulation 
of NOS activity and expression by its own product has 
been raised when Rogers & Ignarro (1992) found that 
during in vitro determination of NOS activity the rate of 
L-citrulline formation was not linear. The above men-
tioned authors showed that addition of oxyhemoglobin 
(a strong NO scavenger) made the rate of NO formation 
linear, while addition of superoxide dismutase (which 
increases the half-life of NO) inhibited NOS activity 
and made the rate of NO production more non-linear. 
As the decrease of NOS activity was observed even 
after admixing authentic NO or exogenous NO donors 
to the enzymatic reaction, the authors for the first 
time hypothesized the existence of binding between 
heme-iron and NO, which was considered to represent 
a negative feedback regulation of NOS activity (Rogers 
& Ignarro, 1992). 
Consequently, the assay was repeated with iNOS from 
activated murine macrophages (Assreuy et al., 1993) and 
rat alveolar macrophages (Griscavage et al., 1993), which 
means that feedback regulation is not only a matter of 
"constitutive" isoforms. Since then, a number of trials 
verified the existence of this negative feedback loop 
both in vitro and in vivo (Park et al., 1994; Buga et al., 
1993; Ravichandran et al., 1995; Grumbach et al., 2005; 
Bernátová et al., 2007b; Zhen et al., 2008).
Chemical basis of feedback regulation of NOS activity
The chemical basis of NO-NOS interaction is not com-
pletely understood. The heme-iron bond in the NOS 
molecule may occur in both reduced (ferrous) and oxi-
dized (ferric) form and even formation of both ferric- and 
ferrous-nitrosyl complexes with NOS exists (Hurshman & 
Marletta, 1995), leading to NOS inhibition.
The ferrous-nitrosyl complex is considered to be a 
natural part of catalysis (Abu-Soud et al., 1995) and it 
is formed during the first seconds after NO synthesis 
initiation by the heme binding of newly generated NO 
(Santolini et al., 2001b). Particular NOS isoforms differ 
by the rate of autoinhibition. For example, the majority 
(70–90%) of nNOS was present at its ferrous-nitrosyl 
complex regardless of the NO concentration in solution 
(Abu-Soud et al., 1995). By contrast, iNOS heme-NO 
complex consists of a rather ferric-nitrosyl complex 
formed rapidly and depending on NO concentration, 
although a minor amount of ferrous heme-NO complex 
forms in iNOS, suggesting that its regulation also involves 
generated NO binding (Santolini et al., 2001b). Regarding 
eNOS, it seems to form relatively little heme-NO complex 
with the lowest formation rate (Abu-Soud et al., 2000).
For all iNOS, eNOS and nNOS, a loss of activity 
appears when heme binds NO that accumulates in a 
solution as a consequence of chemical equilibrium 
(Santolini et al., 2001a). To examine the susceptibility 
of the particular NOS isoforms to self-inhibition by NO, 
Scott and his colleagues (2002) constructed inhibition 
curves of each NOS isoform to NO donor S-nitroso-N-
acetyl-penicillamine (SNAP). The calculated IC50 values 
for SNAP were 1  800  μM for iNOS, 200  μM for eNOS 
and 51 μM for nNOS. The high level of NO produced by 
inducible isoform may thus inhibit the activity of consti-
tutive isoforms, which becomes especially apparent under 
conditions of increased iNOS activity, e.g. in sepsis (Scott 
et al., 2002) or meconium-induced inflammation (Li et al., 
2001).
The existence of negative feedback regulation may 
contribute to the beneficial effect of inhaled NO on per-
sistent pulmonary hypertension or meconium aspiration 
syndrome in newborns (Ichinose et al., 2004). However, 
to date data about the direct effect of inhaled NO on 
pulmonary inflammation processes are missing.
Feedback regulation of NOS expression
After the feedback regulation of NOS activity by NO had 
been proven, the next step was to determine whether 
feedback regulation of NOS expression existed and the 
attention of scientists focused on the regulatory action of 
both exogenous and endogenous NO.
The first observation of NO intervention in tran-
scriptional processes was made by Park et al. (1994) who 
incubated the culture of astroglial cells with hemoglobin 
and found increased iNOS mRNA after induction com-
pared to the control, which was completely abolished in 
the presence of exogenous NO donor. 
Chemical basis of feedback regulation of NOS expression
Now it is clear that NO, whether released from exogenous 
donors or applied in authentic NO solution, is able to 
inhibit iNOS expression in concentrations close to the 
physiological range (Colasanti et al., 1995). This is true 
also for eNOS. The presence of NO donor reduced the 
rate of eNOS mRNA increase, which is the physiologi-
cal reaction of endothelial cells to laminar shear stress 
(Grumbach et al., 2005).
We also know that the promoter region of iNOS gene 
contains several binding sites for NF-κB (Hecker et al., 
1997), which plays a central role in the regulation of NOS 
expression (Colasanti et al., 1995; Kleinert et al., 2004). 
This clarifies also the linkage between inflammation 
and iNOS expression. The inhibitory effect of NO on 
NF-κB was proved also for eNOS (Grumbach et al., 2005, 
Figure 1), however, there is no accordance about the site 
of NO inhibitory action on NF-κB. According to what 
has been found, NO may inhibit activation of NF-κB 
(Colasanti et al., 1995), NF-κB binding to DNA (Park et 
al., 1997) or induce and stabilize the inhibitor of NF-κB 
(Peng et al., 1995; Davis et al., 2004). In addition, it is pos-
sible that NO intervenes with feedback regulation of NOS 
expression at multiple levels. Further, feedback regulation 
of NOS expression was assumed to be transmitted by 66
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cGMP as a decrease of eNOS expression was found after 
pretreatment with exogenous cGMP (Vaziri & Wang, 
1999). From this point of view, the molecular tracks of a 
negative loop between NO and NOS isoform expression 
has not been satisfactorily elucidated as yet. 
Oxidative stress and NOS expression
Considering NF-κB contribution to NOS expression, we 
cannot neglect the role of oxidative stress. The production 
of reactive oxygen species (ROS) during exercise led to 
NF-κB activation and, afterwards, to expression of both 
eNOS and iNOS in rat skeletal muscles (Gomez-Cabrera 
et al., 2005). Moreover, induction of oxidative stress by 
glutathione depletion caused up-regulation of renal and 
aortic eNOS and iNOS in animals (Zhen et al., 2008). This 
finding is logical, because under conditions of oxidative 
stress, the NO regulatory process of NOS expression may 
be interrupted. As O2
– serves as NO scavenger (forming 
peroxynitrite), the bioavailability of NO for the tissue is 
limited. The following up-regulation of NOS has to com-
pensate NO deficiency. However, under conditions of oxi-
dative stress, the essential cofactors of NO synthesis may 
be inactivated and NOS itself may produce ROS and thus 
worsen the situation. Participation of ROS in compensa-
tory NOS expression became apparent after antioxidant 
treatment where eNOS and iNOS were down-regulated in 
rat kidneys, aorta and heart (Vaziri et al., 2000).
Aims for the future
The existence of negative feedback regulation of NOS 
expression and activity by its product NO provides a 
powerful tool for experimental and clinical use. Chronic 
administration of low doses of NOS inhibitor enhances 
NOS activity and NO production in vascular tissues via 
feedback regulation (Kopincová et al., 2008). Thus NO, 
whether inhaled or derived from exogenous NO donors, 
should stop processes leading to massive iNOS expres-
sion and activity in situations when it is detrimental, e.g. 
in inflammatory processes. However, the ”user’s manual” 
for this tool needs to be further elucidated.
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Figure 1. Negative feedback regulatory eff  ect (  — — —    ) of nitric oxide (NO) to endothelial 
nitric oxide synthase (eNOS) expression mediated via nuclear factor κB (NF-κB). 
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